ProteinQure

Decades of research on antibody drug-conjugates, and it's amazing to see how much we still have to learn about how and where they work best. Alternative targeting modalities will be part of the equation. Chat with us at the 36th EORTC-NCI-AACR Symposium. #ENASymp24

"See what you treat and treat what you see." We're proud to share our strategy for AI-enabled radioconjugate discovery at the Canadian innovation workshop of the European Association of Nuclear Medicine (EANM) 2024 Canadian Medical Isotope Ecosystem Canadian Nuclear Isotope Council #EANM2024

We're thrilled to see The Nobel Prize in Chemistry recognizing groundbreaking advancements at the intersection of machine learning and protein design! At ProteinQure, we're proud to build on these achievements to accelerate the development of innovative protein-based therapeutics.

The future of oligonucleotide therapeutics were on display this week at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society. We were pleased to share our early-stage program on kidney-targeted siRNA delivery assisted by computational peptide design. #ots24 #oligomeeting

This is our third program and the most novel one yet! It is still early, but we continue to make new cell types tractable for delivery.

Project Spotlight: ProteinQure (Ontario) Project: AI-driven optimization of a companion radiodiagnostic for a novel breast cancer therapeutic. Triple negative breast cancer (TNBC) presents significant treatment challenges, characterized by a 12% five-year survival rate, limited targeted therapy options, and invasive tests for treatment planning. Sortilin (SORT1), a cell surface and internalizing receptor overexpressed in various cancers, shows promise as a target for delivering high-potency, cytotoxic payloads or isotopes, aimed at maximizing toxicity towards cancer cells whilst minimizing it towards normal cells. ProteinQure has a development candidate (PQ-203) for TNBC, currently in Investigational New Drug (IND) enabling studies. Our modular peptide-drug conjugate comprises a cytotoxic payload conjugated to a peptide targeting SORT1. Building on this, ProteinQure has initiated the development of a companion radiodiagnostic as part of the CMIEDF. Our project will optimize the peptide that could form the basis for a radiodiagnostic (and eventually a radiotherapeutic). 

Project Spotlight: ProteinQure (Ontario) Project: AI-driven optimization of a companion radiodiagnostic for a novel breast cancer therapeutic. Triple negative breast cancer (TNBC) presents significant treatment challenges, characterized by a 12% five-year survival rate, limited targeted therapy options, and invasive tests for treatment planning. Sortilin (SORT1), a cell surface and internalizing receptor overexpressed in various cancers, shows promise as a target for delivering high-potency, cytotoxic payloads or isotopes, aimed at maximizing toxicity towards cancer cells whilst minimizing it towards normal cells. ProteinQure has a development candidate (PQ-203) for TNBC, currently in Investigational New Drug (IND) enabling studies. Our modular peptide-drug conjugate comprises a cytotoxic payload conjugated to a peptide targeting SORT1. Building on this, ProteinQure has initiated the development of a companion radiodiagnostic as part of the CMIEDF. Our project will optimize the peptide that could form the basis for a radiodiagnostic (and eventually a radiotherapeutic). 

Leaders in radioconjugates for oncology, like Fusion Pharmaceuticals, have drawn industry attention to Canada. Thanks to Canadian Medical Isotope Ecosystem, we are eager to advance the development of a targeted radioconjugate program (https://lnkd.in/g2rjuHns). Connect with us at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting! #SNMMI24

ProteinQure is in Chicago for #ASCO24 to discuss the next-generation of cancer treatment. Connect with Lucas Siow or Francine E. Lui, Ph.D. to discuss the road map to bring our peptide-drug conjugate to the patients who need it.

Excited to leverage this opportunity to continue to advance our first internal radio-peptide conjugate program. Ontario and Canada have had some major wins radiopharma (point, fusion amongst others). Hoping to build on their great examples.